C4 Therapeutics, Inc.

NasdaqGS:CCCC Voorraadrapport

Marktkapitalisatie: US$376.5m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

C4 Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

C4 Therapeutics heeft een totaal eigen vermogen van $247.1M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $381.1M en $134.0M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$264.10m
AandelenUS$247.06m
Totaal verplichtingenUS$134.04m
Totaal activaUS$381.09m

Recente financiële gezondheidsupdates

Recent updates

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Oct 02
We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

Aug 09
Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Aug 03
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12
Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29
Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03
New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14
Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10
Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

C4 Therapeutics closes $181M capital raise

Jun 21

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $276.0M ) CCCC } overtreffen de korte termijn passiva ( $54.2M ).

Langlopende schulden: De kortetermijnactiva CCCC ( $276.0M ) overtreffen de langetermijnschulden ( $79.8M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CCCC is schuldenvrij.

Schuld verminderen: CCCC had 5 jaar geleden geen schulden.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: CCCC heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: CCCC heeft voldoende kasruimte voor 2 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 27.1 % per jaar.


Ontdek gezonde bedrijven